蛋白结合型紫杉醇-话题@MedSci - 梅斯（MedSci）

#蛋白结合型紫杉醇#

12篇内容 | 894人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1811571, encodeId=f81918115e17d, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=9 大癌种白蛋白结合型紫杉醇临床应用，只此一篇就够了！, objectType=article, longId=729544, objectId=c228e29544f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c228e29544f9, replyNumber=0, likeNumber=86, createdTime=2022-06-23, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c228e29544f9, moduleTitle=9 大癌种白蛋白结合型紫杉醇临床应用，只此一篇就够了！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c228e29544f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811570, encodeId=596b18115e09b, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施, objectType=article, longId=293056, objectId=308a29305649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=308a29305649, replyNumber=0, likeNumber=97, createdTime=2022-01-11, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=308a29305649, moduleTitle=Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=308a29305649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811568, encodeId=940018115682a, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性, objectType=article, longId=211073, objectId=73fa2110e321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fa2110e321, replyNumber=0, likeNumber=94, createdTime=2022-01-03, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fa2110e321, moduleTitle=Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=73fa2110e321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811569, encodeId=396c18115695c, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, objectType=article, longId=213736, objectId=41a6213e36ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a6213e36ec, replyNumber=0, likeNumber=121, createdTime=2022-03-23, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a6213e36ec, moduleTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=41a6213e36ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811567, encodeId=868f181156e23, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=化疗仍是乳腺癌基础治疗手段，白蛋白结合型紫杉醇有优势, objectType=article, longId=164695, objectId=1d3116469566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d3116469566, replyNumber=0, likeNumber=75, createdTime=2019-08-22, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d3116469566, moduleTitle=化疗仍是乳腺癌基础治疗手段，白蛋白结合型紫杉醇有优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1d3116469566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811566, encodeId=88c61811566ad, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=【2019 CSCO BC】冯继锋、殷咏梅教授：厚积薄发——化疗仍是乳腺癌基础治疗手段，白蛋白结合型紫杉醇有优势, objectType=article, longId=164544, objectId=6d95164544db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d95164544db, replyNumber=0, likeNumber=76, createdTime=2020-02-25, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d95164544db, moduleTitle=【2019 CSCO BC】冯继锋、殷咏梅教授：厚积薄发——化疗仍是乳腺癌基础治疗手段，白蛋白结合型紫杉醇有优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d95164544db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811564, encodeId=8aeb1811564d0, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=J Natl Cancer Inst：TNBC：新辅助蛋白结合型紫杉醇+卡铂vs蛋白结合型紫杉醇+吉西他滨, objectType=article, longId=144214, objectId=35ae14421406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35ae14421406, replyNumber=0, likeNumber=106, createdTime=2018-08-31, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35ae14421406, moduleTitle=J Natl Cancer Inst：TNBC：新辅助蛋白结合型紫杉醇+卡铂vs蛋白结合型紫杉醇+吉西他滨, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=35ae14421406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811565, encodeId=29971811565e2, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, objectType=article, longId=147408, objectId=1ea914e40885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea914e40885, replyNumber=0, likeNumber=67, createdTime=2018-09-16, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea914e40885, moduleTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1ea914e40885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811563, encodeId=65bc1811563cb, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=ANN ONCOL：蛋白结合型紫杉醇治疗复发性小肠腺癌和高CIMP结直肠癌, objectType=article, longId=127469, objectId=9a5712e46903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a5712e46903, replyNumber=0, likeNumber=74, createdTime=2018-07-24, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a5712e46903, moduleTitle=ANN ONCOL：蛋白结合型紫杉醇治疗复发性小肠腺癌和高CIMP结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9a5712e46903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811562, encodeId=c04c1811562ce, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=Lancet Gastroen Heptaol：胃癌二线化疗，白蛋白结合型紫杉醇vs溶剂型紫杉醇, objectType=article, longId=87928, objectId=3b6f8e92863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b6f8e92863, replyNumber=0, likeNumber=82, createdTime=2017-05-05, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6f8e92863, moduleTitle=Lancet Gastroen Heptaol：胃癌二线化疗，白蛋白结合型紫杉醇vs溶剂型紫杉醇, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3b6f8e92863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811561, encodeId=48a31811561fb, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=【ASCO 2012】白蛋白结合型紫杉醇治疗多种肿瘤显优势, objectType=article, longId=7683, objectId=3d86e6835d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d86e6835d, replyNumber=0, likeNumber=137, createdTime=2012-08-21, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d86e6835d, moduleTitle=【ASCO 2012】白蛋白结合型紫杉醇治疗多种肿瘤显优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3d86e6835d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811560, encodeId=dbf5181156096, content=<a href='/topic/show?id=85058868493' target=_blank style='color:#2F92EE;'>#蛋白结合型紫杉醇#</a>, objectTitle=乳腺癌一线治疗新药白蛋白结合型紫杉醇(nab-paclitaxel)和伊沙匹隆(ixabepilone)效果无优势, objectType=article, longId=6990, objectId=9ab6699005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab6699005, replyNumber=0, likeNumber=103, createdTime=2012-10-14, rootId=0, userName=jeanqiuqiu, userId=6f7770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab6699005, moduleTitle=乳腺癌一线治疗新药白蛋白结合型紫杉醇(nab-paclitaxel)和伊沙匹隆(ixabepilone)效果无优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9ab6699005)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

蛋白结合型紫杉醇

2020-05-29

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

9 大癌种白蛋白结合型紫杉醇临床应用，只此一篇就够了！

2022-06-23

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施

2022-01-11

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性

2022-01-03

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析

2022-03-23

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

化疗仍是乳腺癌基础治疗手段，白蛋白结合型紫杉醇有优势

2019-08-22

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

【2019 CSCO BC】冯继锋、殷咏梅教授：厚积薄发——化疗仍是乳腺癌基础治疗手段，白蛋白结合型紫杉醇有优势

2020-02-25

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

J Natl Cancer Inst：TNBC：新辅助蛋白结合型紫杉醇+卡铂vs蛋白结合型紫杉醇+吉西他滨

2018-08-31

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌

2018-09-16

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

ANN ONCOL：蛋白结合型紫杉醇治疗复发性小肠腺癌和高CIMP结直肠癌

2018-07-24

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

Lancet Gastroen Heptaol：胃癌二线化疗，白蛋白结合型紫杉醇vs溶剂型紫杉醇

2017-05-05

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

【ASCO 2012】白蛋白结合型紫杉醇治疗多种肿瘤显优势

2012-08-21

jeanqiuqiu (审核中...)

前往app查看评论内容

#蛋白结合型紫杉醇#

乳腺癌一线治疗新药白蛋白结合型紫杉醇(nab-paclitaxel)和伊沙匹隆(ixabepilone)效果无优势

2012-10-14

科室
- - 订阅+
  - 更多科室
工具
服务